Rigel Pharmaceuticals (NASDAQ:RIGL) Director Ali-Jackson Kamil sold 2,500 shares of the company's common stock on June 22, 2026, generating proceeds of $87,500. The transaction was executed at a price of $35.0 per share and was facilitated through a Rule 10b5-1 trading plan established on November 7, 2025. The sale was specifically designated to cover tax withholding obligations associated with the vesting of restricted stock units, rather than for investment purposes. Following the transaction, Kamil directly retains a position of 10,125 shares in Rigel Pharmaceuticals.
The insider sale comes as RIGL shares trade at $36.55, up modestly from the $35 transaction price. According to InvestingPro analysis, the stock appears undervalued based on Fair Value estimates. The company has delivered a 90% return over the past year, though shares remain 30% below their 52-week high of $52.24. InvestingPro offers 10 additional exclusive tips for RIGL subscribers.
Following this transaction, Mr. Kamil directly holds 10,125 shares of Rigel Pharmaceuticals common stock.
In other recent news, Rigel Pharmaceuticals has reported strong revenue growth for the first quarter of 2026, with net product sales totaling $54.9 million, marking a 26% increase compared to the previous year. TAVALISSE, Rigel’s flagship product, contributed significantly with a 31% growth in sales year-over-year. Despite the positive revenue figures, the company faced investor concerns due to increased costs and a decline in net income. Rigel Pharmaceuticals has maintained its full-year revenue guidance, projecting between $275 million and $290 million. Additionally, Rigel announced a global licensing agreement for Veppanu, a breast cancer drug developed by Arvinas and Pfizer. This agreement grants Rigel exclusive rights for the development, manufacturing, and commercialization of Veppanu. The drug, approved for patients with specific genetic mutations, represents a significant addition to Rigel’s portfolio. These developments reflect Rigel’s strategic efforts to expand its product offerings and strengthen its market position.
RigelFollowAnalyze RIGLIncluded in our AI-picked strategies·Review strategies36.55▲+0.940(+2.64%)Closed·15:59:59·USD36.550.000(0.00%)After Hours·16:10:101D1W6M5YMaxCreated with Highcharts 11.4.813:3014:0014:3015:0015:3016:0017:0017:3018:0018:3019:0019:3035.53636.5Analyze RIGLThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Should you invest $2,000 in RIGL right now?ProPicks AI evaluates RIGL alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if RIGL is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?See More Stocks